BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
September 21 2021 - 10:30AM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced the appointment of James J. Barry, Ph.D.
as an Independent Director to its Board of Directors.
Dr. Barry has more than 30 years of experience in the medical
device industry as an executive and corporate board director.
He is currently the Principal Owner at Convergent Biomedical Group
LLC., a company providing advisory services to the life sciences
industry. Prior to Convergent, Dr. Barry was President and CEO at
InspireMD, Inc. (Nasdaq: NSPR) and platform technology company,
Arsenal Medical. Dr. Barry spent the majority of his career
at Boston Scientific (NYSE: BSX) with increasing roles of
responsibility culminating as Sr. Vice President of Corporate
Technology. While at Boston Scientific, Dr. Barry led the
development and launch of the TAXUS drug-eluting coronary stent
that achieved annual sales exceeding $3 billion.
Dr. Barry is the author of multiple peer-reviewed publications
and holds more than 40 U.S. and international patents. He holds a
Ph.D. in Biochemistry from the University of Massachusetts-Lowell
and a B.A. in Chemistry from St. Anselm College.
“I have always viewed the electrophysiology field as a
tremendous opportunity given the burden heart rhythm disorders have
on the healthcare system. It is a space that can benefit
greatly from innovation, and I am impressed with the PURE EP(tm)
system which appears to be a meaningful advance in signal detection
and should have a positive impact on procedure time and cost. I
look forward to working with the BioSig Board and the management
team to leverage my experience and executive leadership to deliver
on the strategic expansion of the PURE EP(tm) system and the
company’s many pipeline opportunities,” commented Dr. Barry.
“Jim’s accomplishments in the medical device sector are
second-to-none, and we are thrilled that he can join us as our new
Independent Director. Our mission is to empower physicians to make
better procedural decisions through more advanced technological
solutions, and Jim’s industry expertise is perfectly aligned with
our passion for innovation. We look forward to learning from Jim as
we continue to expand our commercial roll-out,” commented Kenneth
L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
The PURE EP(tm) is an FDA 510(k) cleared non-invasive class II
device that aims to drive procedural efficiency and efficacy in
cardiac electrophysiology. To date, over 60 physicians have
completed over 1300 patient cases with the PURE EP(tm) System
across twelve clinical sites.
The Company recently completed its first multi-centered,
prospective clinical trial and presented preliminary clinical data
during the annual Heart Rhythm 2021 convention in July in Boston,
MA.
The Company is in a focused commercial launch of the PURE EP(tm)
System in the Northeast, Texas, and Florida and is in regular use
in some of the country’s leading centers of excellence, including
the Mayo Clinic in Rochester, MN, and St. David’s Medical Center in
Austin, TX.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024